8-K: Pfizer Reports Mixed First Quarter Results, Raises EPS Guidance

Pfizer's first quarter results show a revenue decline due to decreased COVID-19 product sales, but strong growth in other areas and an increased adjusted EPS guidance.

Summary

• Pfizer's first-quarter 2024 revenues were $14.9 billion, a 20% decrease compared to the same period last year.
• This decline is primarily due to a significant drop in sales of Comirnaty and Paxlovid.
• Excluding these COVID-19 products, revenues grew by 11% operationally.
• Reported diluted EPS was $0.55, while adjusted diluted EPS was $0.82, which includes a $0.11 favorable impact from a Paxlovid revenue adjustment.
• The company is on track to achieve at least $4 billion in net cost savings by the end of 2024.
• Pfizer has reaffirmed its full-year 2024 revenue guidance of $58.5 to $61.5 billion and raised its adjusted diluted EPS guidance to $2.15 to $2.35.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong growth in non-COVID products and an increase in EPS guidance, but tempered by significant declines in overall revenue and net income due to reduced COVID-19 product sales.

Positives

• Non-COVID product portfolio showed strong performance with 11% operational revenue growth.
• Vyndaqel family revenues increased significantly by 66% operationally.
• Eliquis and Prevnar families also experienced solid operational growth.
• The company is on track to deliver $4 billion in net cost savings by the end of 2024.
• Adjusted diluted EPS guidance for 2024 has been raised.
• Several new products and recent acquisitions are contributing to revenue growth.
• The company has received regulatory approvals for several key products including Beqvez, Emblaveo, and Prevenar 20.
• Positive clinical trial data was reported for Abrysvo and Adcetris.

Negatives

• Total revenues decreased by 20% compared to the first quarter of 2023.
• Comirnaty revenues declined by 88% operationally.
• Paxlovid revenues declined by 50% operationally.
• Oncology biosimilars revenues decreased by 47% operationally.
• Sulperazon revenues decreased by 45% operationally.
• Ibrance revenues decreased by 7% operationally.
• Reported net income and diluted EPS decreased significantly by 44% compared to the prior year.

Risks

• The company faces risks related to the declining demand for COVID-19 products.
• There are uncertainties regarding the transition to the commercial market for COVID-19 products.
• The company is exposed to competition from biosimilars and generic products.
• There are risks associated with the integration of acquired businesses, such as Seagen.
• The company is subject to regulatory risks and potential legal proceedings.
• Fluctuations in foreign exchange rates could impact financial results.
• The company faces risks related to the outcome of research and development activities.
• There are risks related to the safety and efficacy of in-line products and product candidates.
• The company is exposed to risks related to intellectual property and technology.

Future Outlook

Pfizer reaffirms its full-year 2024 revenue guidance and raises its adjusted diluted EPS guidance, indicating confidence in its cost realignment program and underlying business strength. The company anticipates approximately 90% of Comirnaty sales to occur in the second half of the year, mostly in the fourth quarter.

Management Comments

• Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: 'We delivered strong performance in our non-COVID product portfolio in the first quarter of 2024, including increased revenue from several of our recent commercial launches and acquired products, as well as robust year-over-year growth for several key in-line brands.'
• Dr. Albert Bourla also stated: 'Overall, I am encouraged by a well-executed quarter, setting the tone for the year.'
• David Denton, Chief Financial Officer and Executive Vice President, stated: 'I am very pleased by the strong 11% operational revenue growth of our non-COVID products in the first quarter, demonstrating our focus on commercial execution.'

Industry Context

The results reflect a broader trend in the pharmaceutical industry where companies are adjusting to the post-pandemic environment, with a focus on diversifying revenue streams beyond COVID-19 products. Pfizer's emphasis on its non-COVID portfolio and cost realignment program aligns with this industry-wide shift.

Comparison to Industry Standards

• Pfizer's 11% operational revenue growth in non-COVID products is a positive sign, especially when compared to companies that are still heavily reliant on COVID-19 related sales.
• Companies like Moderna and BioNTech, which have a larger proportion of their revenue from COVID-19 vaccines, are likely facing similar challenges with declining sales in this area.
• Pfizer's diversified portfolio, including recent acquisitions like Seagen, positions it better than companies with a narrower product range.
• The cost realignment program is similar to initiatives undertaken by other large pharmaceutical companies to improve efficiency and profitability.
• The adjusted EPS guidance increase suggests that Pfizer is managing its costs effectively and is confident in its future performance, which is a positive signal compared to companies that are struggling to maintain profitability.

Stakeholder Impact

• Shareholders will be impacted by the decrease in revenue and net income, but may be encouraged by the increased EPS guidance and cost savings program.
• Employees may be affected by the cost realignment program, which includes employee terminations.
• Customers will benefit from the continued development and availability of new and existing products.
• Suppliers may be impacted by changes in the company's supply chain and manufacturing operations.
• Creditors will be impacted by the company's financial performance and debt levels.

Next Steps

• The company intends to submit data to regulatory agencies to expand the age group for Abrysvo to 18 years of age and older.
• Pfizer plans to share the ECHELON-3 data with the FDA to potentially support regulatory filing in the U.S.
• The company will continue to progress its cost realignment program.
• Pfizer will continue to focus on data-driven opportunities across several key growth brands.
• The company will continue to monitor the market for COVID-19 products and adjust its strategy accordingly.

Key Dates

Keywords

Pfizer, Pharmaceuticals, Revenue, Earnings, COVID-19, Comirnaty, Paxlovid, EPS, Cost Savings, Oncology, Biopharma, Vaccines, Therapeutics, Acquisition, Seagen